Algernon Pharmaceuticals Inc. (AGN.CN)
CAD 0.07
(0.0%)
CAD 0.07
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.19 Million CAD | -13.45% |
| 2022 | 6.05 Million CAD | -24.78% |
| 2021 | 8.05 Million CAD | -7.21% |
| 2020 | 8.67 Million CAD | 353.37% |
| 2019 | 1.91 Million CAD | 101.77% |
| 2018 | 948.55 Thousand CAD | -34.67% |
| 2017 | 1.45 Million CAD | -50.52% |
| 2016 | 2.93 Million CAD | 301.73% |
| 2015 | 730.46 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1004.21 CAD | -99.81% |
| 2024 Q1 | 521.97 Thousand CAD | -47.05% |
| 2024 Q3 | 459.57 Thousand CAD | 45664.73% |
| 2023 Q4 | 985.84 Thousand CAD | -12.6% |
| 2023 Q2 | 1.24 Million CAD | -33.64% |
| 2023 FY | 5.24 Million CAD | -13.45% |
| 2023 Q1 | 1.88 Million CAD | -15.21% |
| 2023 Q3 | 1.12 Million CAD | -9.6% |
| 2022 Q3 | 801.16 Thousand CAD | -56.38% |
| 2022 Q4 | 2.21 Million CAD | 176.8% |
| 2022 FY | 6.05 Million CAD | -24.78% |
| 2022 Q2 | 1.83 Million CAD | 52.92% |
| 2022 Q1 | 1.2 Million CAD | 119.95% |
| 2021 Q4 | 546.03 Thousand CAD | -67.43% |
| 2021 Q1 | 3.44 Million CAD | 20.36% |
| 2021 Q2 | 2.38 Million CAD | -30.59% |
| 2021 Q3 | 1.67 Million CAD | -29.81% |
| 2021 FY | 8.05 Million CAD | -7.21% |
| 2020 Q2 | 793.77 Thousand CAD | 208.6% |
| 2020 Q4 | 2.85 Million CAD | -40.04% |
| 2020 Q3 | 4.76 Million CAD | 500.6% |
| 2020 Q1 | 257.21 Thousand CAD | -39.58% |
| 2020 FY | 8.67 Million CAD | 353.37% |
| 2019 FY | 1.91 Million CAD | 101.77% |
| 2019 Q4 | 425.69 Thousand CAD | -20.1% |
| 2019 Q3 | 532.76 Thousand CAD | 19.19% |
| 2019 Q2 | 446.99 Thousand CAD | -12.09% |
| 2019 Q1 | 508.46 Thousand CAD | 162.14% |
| 2018 Q1 | 196.25 Thousand CAD | -33.29% |
| 2018 FY | 948.55 Thousand CAD | -34.67% |
| 2018 Q4 | 193.96 Thousand CAD | -51.2% |
| 2018 Q3 | 397.46 Thousand CAD | 147.08% |
| 2018 Q2 | 160.86 Thousand CAD | -18.04% |
| 2017 Q1 | 521.66 Thousand CAD | 88.15% |
| 2017 Q2 | 325.68 Thousand CAD | -37.57% |
| 2017 Q3 | 310.41 Thousand CAD | -4.69% |
| 2017 Q4 | 294.21 Thousand CAD | -5.22% |
| 2017 FY | 1.45 Million CAD | -50.52% |
| 2016 FY | 2.93 Million CAD | 301.73% |
| 2016 Q4 | 277.25 Thousand CAD | -41.43% |
| 2016 Q3 | 473.38 Thousand CAD | -76.6% |
| 2016 Q2 | 2.02 Million CAD | 1159.46% |
| 2016 Q1 | 160.64 Thousand CAD | -69.5% |
| 2015 FY | 730.46 Thousand CAD | 0.0% |
| 2015 Q4 | 526.67 Thousand CAD | 158.44% |
| 2015 Q3 | 203.79 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Asep Medical Holdings Inc | 7.74 Million CAD | 32.946% |
| BetterLife Pharma Inc. | 3.24 Million CAD | -60.222% |
| BioVaxys Technology Corp. | 2.4 Million CAD | -116.082% |
| ChitogenX Inc. | 2.83 Million CAD | -83.449% |
| Rapid Dose Therapeutics Corp. | 4.2 Million CAD | -23.361% |
| Defence Therapeutics Inc. | 12.65 Million CAD | 58.979% |
| Entheon Biomedical Corp. | 564.31 Thousand CAD | -819.981% |
| Gemina Laboratories Ltd. | 5.08 Million CAD | -2.078% |
| Glow Lifetech Corp. | 25.71 Thousand CAD | -20088.968% |
| Lexston Life Sciences Corp. | 674.71 Thousand CAD | -669.446% |
| Pharmala Biotech Holdings Inc. | 1.21 Million CAD | -326.572% |
| Doseology Sciences Inc. | 72.08 Thousand CAD | -7101.844% |
| MYND Life Sciences Inc. | 1.47 Million CAD | -252.023% |
| Nova Mentis Life Science Corp. | 1.2 Million CAD | -331.805% |
| PharmaTher Holdings Ltd. | 3.04 Million CAD | -70.547% |
| PreveCeutical Medical Inc. | 963.12 Thousand CAD | -439.037% |
| Telescope Innovations Corp. | 6.35 Million CAD | 18.272% |